cell-stem-cell

name	cell-stem-cell
description	Use when targeting Cell Stem Cell or deciding whether a stem-cell or regenerative-biology manuscript fits this Cell Press venue. Encodes the journal's fit, framing, method-and-evidence bar, house style, official-submission re-check, and desk-reject heuristics.

Cell Stem Cell (cell-stem-cell)

Journal positioning

Cell Stem Cell is the Cell Press flagship for stem-cell biology, regenerative medicine, and reprogramming. It publishes mechanistic studies in which stem or progenitor cells are the central biological unit — from pluripotency regulation and lineage specification through tissue-specific adult stem cells, organoids, and cellular reprogramming. The journal bridges fundamental developmental and cell biology with translational and therapeutic applications, but it demands mechanistic depth throughout: a paper that is primarily clinical or descriptive, without a molecular or cellular mechanism, does not fit. The readership spans developmental biologists, cell biologists, geneticists, and regenerative-medicine researchers; the advance must be legible and significant to this combined audience.

This skill is a fit / venue-selection / re-framing tool. It does not replace the journal's current official submission guidelines. Before submitting, re-check the live author instructions on the Cell Press site.

When to trigger

• The author names Cell Stem Cell as the target venue.
• A paper in stem-cell biology, reprogramming, or organoid biology needs the Cell Press flagship in the field.
• A mechanistic study of cell fate, lineage commitment, or tissue regeneration has both molecular depth and in vivo relevance and the author is choosing between Cell Stem Cell, cell, and developmental-cell.
• The author needs Cell Stem Cell's specific evidence bar (mechanism + in vivo requirement), STAR Methods obligations, and desk-reject patterns before submitting.

Scope & topic fit

• Pluripotency: mechanisms of pluripotent stem-cell (PSC) maintenance, exit, and re-entry; transcription-factor networks, epigenetic regulation, and signaling in ESCs and iPSCs.
• Cellular reprogramming: direct reprogramming of somatic cells, transdifferentiation, and mechanistic understanding of the barriers and determinants.
• Lineage specification and organogenesis: specification of tissue progenitors from PSCs or in vivo, with mechanistic insight into the decision points.
• Adult stem cells: identity, niche interactions, self-renewal vs. differentiation decisions, and their regulation in homeostasis and regeneration.
• Organoids and advanced stem-cell models: only when the model is used to answer a mechanistic question or validate a therapeutic concept — technology development alone is insufficient.
• Translational and disease applications: disease modeling with iPSCs, gene-correction approaches, or cell-therapy strategies — but always with a mechanistic underpinning that goes beyond the clinical observation.
• Aging and stem-cell dysfunction: mechanisms by which stem-cell activity declines or becomes aberrant with age or disease.

Method & evidence bar

• Mechanism plus in vivo relevance is the standard combination: a purely in vitro mechanistic study must have compelling reason why in vivo validation cannot or need not be done; most papers require at least one in vivo or ex vivo component.
• For PSC/reprogramming papers: multiple independent cell lines, rigorous pluripotency authentication (teratoma, chimera, or equivalent), and appropriate passage-number controls.
• For adult stem-cell papers: lineage tracing or clonal analysis in vivo is often required to demonstrate stem-cell identity and behavior; FACS isolation with validated markers is the minimum.
• STAR Methods is mandatory: complete experimental details, Key Resources Table (all antibodies, cell lines, mouse strains, plasmids, software with identifiers/RRIDs), and data/code availability at initial submission.
• For sequencing or omics data: deposition in GEO, SRA, or equivalent; accession numbers before acceptance.
• Statistics must distinguish biological from technical replicates, report effect sizes, and specify tests throughout.
• For human iPSC work: donor consent and ethics approval are required; for any human embryo or hESC work, re-check current ethical compliance requirements carefully.

Structure & house style

• Cell Stem Cell publishes Articles, Short Reports (re-check current types and length limits), and occasionally Resource papers; the standard mechanistic paper is an Article.
• STAR Methods is appended after main references with defined subheadings and the Key Resources Table; it must be complete at initial submission.
• Figures must build the mechanistic argument in stages; a model figure at the end of the main figures is standard, depicting the proposed molecular/cellular mechanism.
• Graphical abstracts and eTOC blurbs are required or strongly expected — re-check current Cell Press format and resolution requirements.
• Supplemental information carries secondary validations, extended characterization of additional cell lines, and supporting datasets — not core evidence.
• The Discussion must clearly delineate translational implications where relevant, but without over-claiming therapeutic readiness.

Official-submission checklist

• Before giving submission-ready advice, read ../../resources/source-basis.md and ../../resources/official-source-map.md; start from the official source anchors for this journal family, then cite the current journal-specific page you checked.
• Search the live site for "Cell Stem Cell author instructions" and follow the current Cell Press version.
• Re-check article types, word and figure limits per type, and abstract format.
• Re-check STAR Methods requirements: Key Resources Table format, RRID requirements, reagent and cell-line identification standards.
• Re-check sequencing/omics data deposition requirements (GEO, SRA) and accession-number submission timeline.
• Re-check ethics requirements for human iPSC/ESC work, human embryo research, and patient-derived samples — this area has jurisdiction-specific regulations that change; re-check the current Cell Press ethics policy carefully.
• Re-check graphical abstract format, eTOC blurb length, competing-interests and funding disclosure, and AI-use disclosure.
• If the live official instructions conflict with this skill, the official instructions win.

Pre-submission self-check

• The paper is mechanistic at the level of the stem or progenitor cell: a cellular or molecular mechanism is resolved, not just described.
• In vivo relevance is demonstrated (lineage tracing, transplantation, or animal model) or a compelling exception is justified.
• STAR Methods is complete, including Key Resources Table with RRIDs for all antibodies, cell lines, and mouse strains.
• PSC lines are authenticated by appropriate assay; adult stem-cell identity is validated by lineage tracing or equivalent.
• Ethics documentation for human cell sources is confirmed; consent and IRB approvals are in place.
• Sequencing data accession numbers are confirmed or in process; graphical abstract is drafted.

Common desk-reject triggers

• Descriptive characterization of stem-cell behavior without a mechanism: showing that a factor affects differentiation is not sufficient — how and why must be mechanistically addressed.
• STAR Methods is absent or the Key Resources Table is missing cell-line and antibody identifiers — Cell Press editors check this at intake.
• In vitro-only mechanistic study for a question where in vivo validation is feasible and expected by the field.
• An organoid or iPSC technology paper where the technology is the contribution and no mechanistic or disease question is answered — technology-development papers need an application driving a discovery.
• The paper is a clinical trial or cohort study without a mechanistic stem-cell component — that paper belongs in a clinical or translational journal.
• Missing graphical abstract or eTOC blurb at submission.

Re-routing decision

• The mechanistic advance is at Cell-level conceptual significance and the biology extends beyond stem cells → cell.
• Developmental mechanism broader than adult stem cells and in vivo, not requiring PSC context → developmental-cell.
• The advance is in cell biology broadly, not specifically stem/progenitor cells → nature-cell-biology.
• Mechanistic molecular biology at biochemical/structural depth underlying a stem-cell process → molecular-cell.
• Solid stem-cell advance below Cell Stem Cell's mechanistic depth → the-embo-journal, plos-biology, or a specialist developmental journal.

Output format

[Fit] High / Medium / Low (one-line reason)
[Target] Cell Stem Cell
[Topic tags] <2–3 closest topics>
[Method/evidence] <is there a mechanistic advance with in vivo relevance and STAR Methods-ready documentation?>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <STAR Methods / Key Resources Table / PSC authentication / ethics/consent / data deposition / graphical abstract>
[Re-route suggestion] <if not a fit, a better-matched venue>